Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-9q27g Total loading time: 0 Render date: 2024-07-16T19:23:10.795Z Has data issue: false hasContentIssue false

11.2 - Non-surgical treatment

from 11 - Treatment of cholangiocarcinoma

Published online by Cambridge University Press:  04 August 2010

By
Orit Gutfeld ,
Charlie Pan ,
Gazala N. Khan  and
Mark M. Zalupski
Edited by
Hero K. Hussain  and
Isaac R. Francis
Hero K. Hussain
Affiliation:
University of Michigan Medical School, Ann Arbor
Isaac R. Francis
Affiliation:
University of Michigan Medical School, Ann Arbor
Get access

Summary

This chapter outlines the available data on the role and use of radiotherapy (RT) in the treatment of biliary malignancies. Adjuvant, definitive, and palliative treatment are discussed for each different site along the biliary tract. The concepts, considerations, and techniques for upper abdominal RT are discussed in detail in Chapter 7.2a.

Postoperative radiotherapy

Surgery is the only potentially curative treatment for patients with biliary carcinoma. However, even with complete resection, the recurrence rate is high and long-term survival is poor. Local recurrence is a common pattern of failure and is associated with significant morbidity and mortality related to hepatobiliary complications. Adjuvant RT can potentially improve local control and survival, but data on its role in this setting are limited. Most of the data are derived from retrospective, single-institution experiences with possible selection bias favoring adjuvant treatments in well-performing patients or in patients with poor prognostic factors. Interpretation of these studies is further complicated by heterogeneity of disease stage, type of resection, and a variety of RT techniques and doses.

Intrahepatic cholangiocarcinoma

Most patients with intrahepatic cholangiocarcinoma (IHC) are not candidates for resection at presentation, mostly because of advanced disease within the liver. After resection, median and 5-year survival are 19 to 37.5 months and 13.6–40%, respectively. The majority of recurrences involve the liver, either alone or in combination with distant sites. Survival is directly related to the ability to obtain negative surgical margins and the absence of regional lymph-node involvement.

Type
Chapter
Information
Primary Carcinomas of the Liver , pp. 195 - 213
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Endo, I, Gonen, M, Yopp, AC, et al. Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248(1): 84–96.CrossRefGoogle ScholarPubMed
Isa, T, Kusano, T, Shimoji, H, Takeshima, Y, Muto, Y, and Furukawa, M. Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma. Am J Surg 2001; 181(6): 507–11.CrossRefGoogle ScholarPubMed
Valverde, A, Bonhomme, N, Ferges, O, et al. Resection of intrahepatic cholangiocarcinoma: A western experience. J Hepatobiliary Pancreat Surg 1999; 6: 122–7.CrossRefGoogle ScholarPubMed
Madariaga, JR, Iwatsuki, S, Todo, S, Lee, RG, Irish, W, and Starzl, TE. Liver resection for hilar and peripheral cholangiocarcinomas: A study of 62 cases. Ann Surg 1998; 227(1): 70–9.CrossRefGoogle ScholarPubMed
Jan, YY, Yeh, CN, Yeh, TS, Hwang, TL, and Chen, MF. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg 2005; 29(7): 894–8.CrossRefGoogle ScholarPubMed
Weber, SM, Jarnagin, WR, Klimstra, D, DeMatteo, RP, Fong, Y, and Blumgart, LH. Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001; 193(4): 384–91.CrossRefGoogle Scholar
Shinohara, ET, Mitra, N, Guo, M, and Metz, JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008; 72(5): 1495–501.CrossRefGoogle ScholarPubMed
DeOliveira, ML, Cunningham, SC, Cameron, JL, et al. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245(5): 755–62.CrossRefGoogle Scholar
Kosuge, T, Yamamoto, J, Shimada, K, Yamasaki, S, and Makuuchi, M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230(5): 663–71.CrossRefGoogle ScholarPubMed
Jarnagin, WR, Fong, Y, DeMatteo, RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234(4): 507–17.CrossRefGoogle ScholarPubMed
Gerhards, MF, Gulik, TM, Gonzáles Gonzáles, D, Rauws, EA, and Gouma, DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003; 27(2): 173–9.Google ScholarPubMed
Gonzáles Gonzáles, D, Gerard, J, Maners, AW, et al. Results of radiation therapy in carcinoma of the proximal bile duct (Klatskin tumor). Semin Liver Dis 1990; 10(2): 131–41.CrossRefGoogle Scholar
Pitt, HA, Nakeeb, A, Abrams, RA, et al. Perihilar cholangiocarcinoma: Postoperative radiotherapy does not improve survival. Ann Surg 1995; 221(6): 788–97.CrossRefGoogle Scholar
Cameron, JL, Pitt, HA, Zinner, MJ, Kaufman, SL, and Coleman, J. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg 1990; 159(1): 91–7.CrossRefGoogle ScholarPubMed
Nakeeb, A and Pitt, HA. Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HPB (Oxford) 2005; 7(4): 278–82.CrossRefGoogle ScholarPubMed
Hughes, MA, Frassica, DA, Yeo, CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007; 68(1): 178–82.CrossRefGoogle ScholarPubMed
Kresl, JJ, Schild, SE, Henning, GT, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 2002; 52(1): 167–75.CrossRefGoogle ScholarPubMed
Mahe, M, Stampfli, C, Romestaing, P, and Salerno, N. Primary carcinoma of the gall-bladder: Potential for external radiation therapy. Radiother Oncol 1994; 33: 204.CrossRefGoogle ScholarPubMed
Nakeeb, A, Tran, KQ, Black, MJ, et al. Improved survival in resected biliary malignancies. Surgery 2002; 132: 555.CrossRefGoogle ScholarPubMed
Ben-David, MA, Griffith, KA, Abu-Isa, E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2006; 66(3): 772–9.CrossRefGoogle ScholarPubMed
Houry, S, Barrier, A, and Huguier, M. Irradiation therapy for gallbladder carcinoma: Recent advances. J Hepatobiliary Pancreat Surg 2001; 8(6): 518–24.CrossRefGoogle ScholarPubMed
Todoroki, T, Kawamoto, T, Otsuka, M, et al. Benefits of combining radiotherapy with aggressive resection for Stage IV gallbladder cancer. Hepato-Gastroenterology 1999; 46(27): 1585–91.Google ScholarPubMed
Czito, BG, Hurwitz, HI, Clough, RW, et al. Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: A 23-year experience. Int J Radiat Oncol Biol Phys 2005; 62(4): 1030–4.CrossRefGoogle ScholarPubMed
Itoh, H, Nishijima, K, Kurosaka, Y, et al. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig Dis Sci 2005; 50(12): 2231–42.CrossRefGoogle ScholarPubMed
Chao, TC and Greager, JA. Primary carcinoma of the gallbladder. J Surg Oncol 1991; 46(4): 215–21.CrossRefGoogle ScholarPubMed
Jarnagin, WR, Ruo, L, Little, SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: Implications for adjuvant therapeutic strategies. Cancer 2003; 98(8): 1689–700.CrossRefGoogle ScholarPubMed
Wang, SJ, Fuller, CD, Kim, JS, Sittig, DF, Thomas, CR, and Ravdin, PM. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol 2008; 26(13): 2112–17.CrossRefGoogle ScholarPubMed
Nathan, H, Pawlik, TM, Wolfgang, CL, Choti, MA, Cameron, JL, and Schulick, RD. Trends in survival after surgery for cholangiocarcinoma: A 30-year population-based SEER database analysis. J Gastrointest Surg 2007; 11(11): 1488–97.CrossRefGoogle ScholarPubMed
,National Cancer Comprehensive Network (NCCN). NCCN clinical practice guidelines in oncology, hepatobiliary cancers V.2.2009. Available from: http://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf. Accessed August 5, 2009.
McMasters, KM, Tuttle, TM, Leach, SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997; 174(6): 605–8; discussion 608–9.CrossRefGoogle ScholarPubMed
Rea, DJ, Heimbach, JK, Rosen, CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242(3): 451–8; discussion 458–61.Google ScholarPubMed
Sudan, D, DeRoover, A, Chinnakotla, S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002; 2(8): 774–9.CrossRefGoogle ScholarPubMed
Grove, MK, Hermann, RE, Vogt, DP, and Broughan, TA. Role of radiation after operative palliation in cancer of the proximal bile ducts. Am J Surg 1991; 161(4): 454–8.CrossRefGoogle ScholarPubMed
Crane, CH, Macdonald, KO, Vauthey, JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002; 53(4): 969–74.CrossRefGoogle ScholarPubMed
Brunner, TB, Schwab, D, Meyer, T, and Sauer, R. Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlenther Onkol 2004; 180(12): 751–7.CrossRefGoogle ScholarPubMed
Foo, ML, Gunderson, LL, Bender, CE, and Buskirk, SJ. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997; 39(4): 929–35.CrossRefGoogle ScholarPubMed
Morganti, AG, Trodella, L, Valentini, V, et al. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 2000; 46(4): 913–19.CrossRefGoogle ScholarPubMed
Takamura, A, Saito, H, Kamada, T, et al. Intraluminal low-dose-rate Ir-192 brachytherapy combined with external beam radiotherapy and biliary stenting For unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 2003; 57(5): 1357–65.CrossRefGoogle Scholar
Ben-Josef, E, Normolle, D, Ensminger, WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23(34): 8739–47.CrossRefGoogle ScholarPubMed
Tse, RV, Hawkins, M, Lockwood, G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26(4): 657–64.CrossRefGoogle ScholarPubMed
Takada, T, Amano, H, Yasuda, H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95(8): 1685–95.Google ScholarPubMed
Kajanti, M and Pyrhonen, S. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 1994; 17(3): 223–6.CrossRefGoogle ScholarPubMed
Harvey, JH, Smith, FP, and Schein, PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2(11): 1245–8.CrossRefGoogle ScholarPubMed
Falkson, G, MacIntyre, JM, and Moertel, CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54(6): 965–9.3.0.CO;2-X>CrossRefGoogle ScholarPubMed
Takada, T, Kato, H, Matsushiro, T, Nimura, Y, Nagakawa, T, and Nakayama, T. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51(5): 396–400.CrossRefGoogle ScholarPubMed
Glimelius, B, Hoffman, K, Sjoden, PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7(6): 593–600.CrossRefGoogle ScholarPubMed
Davis, HL, Ramirez, G, and Ansfield, FJ. Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy. Cancer 1974; 33(1): 193–7.3.0.CO;2-S>CrossRefGoogle ScholarPubMed
Ducreux, M, Rougier, P, Fandi, A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998; 9(6): 653–6.CrossRefGoogle ScholarPubMed
Taieb, J, Mitry, E, Boige, V, et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 2002; 13(8): 1192–6.CrossRefGoogle ScholarPubMed
Ellis, PA, Norman, A, Hill, A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 1995; 31A(10): 1594–8.CrossRefGoogle Scholar
Lee, MA, Woo, IS, Kang, JH, Hong, YS, and Lee, KS. Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol 2004; 130(6): 346–50.CrossRefGoogle Scholar
Rao, S, Cunningham, D, Hawkins, RE, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92(9): 1650–4.CrossRefGoogle ScholarPubMed
Patt, YZ, Hassan, MM, Lozano, RD, et al. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 2001; 7(11): 3375–80.Google ScholarPubMed
Patt, YZ, Jones, DV., Hoque, A, et al. Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996; 14(8): 2311–15.CrossRefGoogle ScholarPubMed
Park, SH, Park, YH, Lee, JN, et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer 2006; 106(2): 361–5.CrossRefGoogle ScholarPubMed
Patt, YZ, Hassan, MM, Aguayo, A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101(3): 578–86.CrossRefGoogle ScholarPubMed
Knox, JJ, Hedley, D, Oza, A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial. J Clin Oncol 2005; 23(10): 2332–8.CrossRefGoogle ScholarPubMed
Burris, H and Storniolo, AM. Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33(Suppl 1): S18–22.CrossRefGoogle ScholarPubMed
Tsavaris, N, Kosmas, C, Gouveris, P, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22(2): 193–8.CrossRefGoogle ScholarPubMed
Park, JS, Oh, SY, Kim, SH, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: A phase II study. Jpn J Clin Oncol 2005; 35(2): 68–73.CrossRefGoogle ScholarPubMed
von Delius, S, Lersch, C, Schulte-Frohlinde, E, Mayr, M, Schmid, RM, and Eckel, F. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 2005; 5(1): 61.CrossRefGoogle Scholar
Penz, M, Kornek, GV, Raderer, M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12(2): 183–6.CrossRefGoogle ScholarPubMed
Alberts, SR, Al-Khatib, H, Mahoney, MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: A North Central Cancer Treatment Group phase II trial. Cancer 2005; 103(1): 111–18.CrossRefGoogle ScholarPubMed
Riechelmann, RP, Townsley, CA, Chin, SN, Pond, GR, and Knox, JJ. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007; 110(6): 1307–12.CrossRefGoogle ScholarPubMed
Cho, JY, Paik, YH, Chang, YS, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 2005; 104(12): 2753–8.CrossRefGoogle ScholarPubMed
Thongprasert, S, Napapan, S, Charoentum, C, and Moonprakan, S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16(2): 279–81.CrossRefGoogle ScholarPubMed
Park, BK, Kim, YJ, Park, JY, et al. Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastroenterol Hepatol 2006; 21(6): 999–1003.CrossRefGoogle ScholarPubMed
Kim, ST, Park, JO, Lee, J, et al. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006; 106(6): 1339–46.CrossRefGoogle ScholarPubMed
Harder, J, Riecken, B, Kummer, O, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006; 95(7): 848–52.CrossRefGoogle ScholarPubMed
Sanz-Altamira, PM, O'Reilly, E, Stuart, KE, et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 2001; 12(4): 501–4.CrossRefGoogle ScholarPubMed
Bhargava, P, Jani, CR, Savarese, DM, O'Donnell, JL, Stuart, KE, and Rocha, Lima CM. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: Preliminary report. Oncology (Williston Park) 2003; 17(9 Suppl 8): 23–6.Google ScholarPubMed
Kuhn, R, Hribaschek, A, Eichelmann, K, Rudolph, S, Fahlke, J, and Ridwelski, K. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 2002; 20(3): 351–6.CrossRefGoogle ScholarPubMed
Papakostas, P, Kouroussis, C, Androulakis, N, et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 2001; 37(15): 1833–8.CrossRefGoogle ScholarPubMed
Jones, DV, Lozano, R, Hoque, A, Markowitz, A, and Patt, YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996; 14(8): 2306–10.CrossRefGoogle ScholarPubMed
Woodburn, JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82(2–3): 241–50.CrossRefGoogle ScholarPubMed
Lee, CS and Pirdas, A. Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. Pathol Res Pract 1995; 191(11): 1087–91.CrossRefGoogle ScholarPubMed
Philip, PA, Mahoney, MR, Allmer, C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24(19): 3069–74.CrossRefGoogle ScholarPubMed
Hezel, AF and Zhu, AX. Systemic therapy for biliary tract cancers. Oncologist 2008; 13(4): 415–23.CrossRefGoogle ScholarPubMed
Hida, Y, Morita, T, Fujita, M, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res 1999; 19(3B): 2257–60.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×